PMID- 19642459
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20151119
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 64
IP  - 5-6
DP  - 2009 May-Jun
TI  - [Monoclonal antibodies and breast cancer. Current therapeutic progress].
PG  - 279-83
AB  - About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement 
      of our knowledge of altered molecular events leading to the proliferation of 
      tumor cells has resulted in the development of targeted therapies in subgroups of 
      cancers. One of the first validation of targeted therapy is the anti-HER-2 
      monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of 
      human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of 
      invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane 
      domain and is only active in tumor with HER2 gene amplification detected by 
      fluorescence in situ hybridization (FISH). The results from randomized trials 
      have rapidly lead to the approvement of the drug in the metastatic and then in 
      the adjuvant setting. Another targeted therapy, also approved in the treatment of 
      breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular 
      Endothelial Growth Factor) activity. We will review the benefit of these targeted 
      therapies in breast cancer and their role in the treatment of breast cancer.
FAU - Collignon, J
AU  - Collignon J
AD  - Service d'Oncologie Medicale, CHU de Liege, Belgique.
FAU - Gennigens, C
AU  - Gennigens C
FAU - Rorive, A
AU  - Rorive A
FAU - Coucke, P
AU  - Coucke P
FAU - Lifrange, E
AU  - Lifrange E
FAU - Maweja, S
AU  - Maweja S
FAU - Fillet, G
AU  - Fillet G
FAU - Jerusalem, G
AU  - Jerusalem G
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Anticorps monoclonaux et cancer du sein. Actualites therapeutiques.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bevacizumab
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Receptor, ErbB-2/antagonists & inhibitors
MH  - Trastuzumab
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
EDAT- 2009/08/01 09:00
MHDA- 2009/09/16 06:00
CRDT- 2009/08/01 09:00
PHST- 2009/08/01 09:00 [entrez]
PHST- 2009/08/01 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
PST - ppublish
SO  - Rev Med Liege. 2009 May-Jun;64(5-6):279-83.